✦ LIBER ✦

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

✍ Scribed by Brodszky, Valentin; Baji, Petra; Balogh, Orsolya; Péntek, Márta

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Budget Impact Analysis of Biosimilar Inf

✍ Brodszky, V.; Péntek, M.; Baji, P.; Balogh, O.; V. Hevér, N.; Gulacsi, L. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Introduction of an Infliximab Biosimilar

✍ McCarthy, G.; Ebel Bitoun, C.; Guy, H. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PMS45 Cost-Utility and Budget Impact Ana

✍ N. Maniadakis; D. Boumpas; G. Kourlaba; P. Christou; I. Anargiros; E. Smets; O P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Real-world effectiveness of abatacept fo

✍ Nüßlein, Hubert G; Alten, Rieke; Galeazzi, Mauro; Lorenz, Hanns-Martin; Boumpas, 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 315 KB